Cervical pessary vs vaginal progesterone for the prevention of preterm birth in women with twin pregnancies and a short cervix: an economic analysis alongside a randomized controlled trial.
To compare the costs and effects of cervical pessary versus vaginal progesterone in women with twin pregnancies and a short cervix. We performed an economic analysis alongside a randomised controlled trial that compared cervical pessary to vaginal progesterone in women with twin pregnancy and a cervical length <38 mm. Main outcome measure was morbidity-free survival neonate. Data on pregnancy outcomes, maternal morbidity and neonatal complications were collected prospectively from medical files; other additional information was obtained via patient telephonic questionnaires. The incremental cost-effectiveness ratio (ICER) was calculated as the incremental cost to achieve one extra morbidity-free survival neonate in the pessary group compared to progesterone group. Probabilistic sensitivity analysis (PSA) and a cost-effectiveness acceptability curve (CEAC) were also performed. Between March 4th 2016 and June 3rd 2017, we screened 1,113 women with twin pregnancies, of whom 300 women fulfilled the inclusion criteria and gave informed consent. These women were randomly assigned to cervical pessary (n=150) or vaginal progesterone (n=150). The rate of morbidity-free survival neonate was significantly higher in the pessary group than that in the progesterone group (241 [81.4%] versus 219 [73.5%], relative risk [RR] 1.11, 95% confidence interval [CI] 1.02 to 1.21, p=0.02, respectively). The mean total cost per woman was 3,148 EUR in the pessary group versus 3,571 EUR in the progesterone group (mean difference -423 EUR, 95% CI -841.8 to -3.3, p=0.048). The cost per morbidity-free survival neonate was significantly lower in the pessary group than that in the progesterone group (2,492 vs. 2,639 EUR, absolute difference -147, 95% CI, -284 to 10; p=0.035). In women with twin pregnancies and a short cervix, cervical pessary significantly improves the rate of morbidity-free survival neonate while reducing costs as compared to vaginal progesterone. This article is protected by copyright. All rights reserved.